Plasma 3 alpha-androstanediol glucuronide in normal children and in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. 1997

L A Lopes, and C Catzeflis, and I Cicotti, and C Rey, and P C Sizonenko
Department of Pediatrics, Geneva Cantonal Hospital, Geneva, Switzerland.

Monitoring therapy for congenital adrenal hyperplasia (CAH) due to 21-hydroxylase is difficult, although plasma determinations of 17 alpha-hydroxyprogesterone (17OHP), delta 4-androstenedione (delta 4A) and testosterone are helpful. We have studied the usefulness of monitoring plasma 3 alpha-androstanediol glucuronide (3 alpha-AG) in group of 24 CAH patients aged from birth to 18 years. For comparison, normal values for age and pubertal stage were determined in a control group of 115 girls and 118 boys. Mean plasma levels were higher during the first year of life, decreased to a nadir between 1 and 4 years, and increased steadily thereafter, there was also a significant increase with pubertal stage. In 24 pairs of blood samples obtained at the time of venopuncture and 2 h after, 3 alpha-AG levels did not change (p > 0.05) demonstrating that 3 alpha-AG levels were not affected by stress. In the patients with CAH, positive correlations between plasma 3 alpha-AG and delta 4A (females, r = 0.73; males, r = 0.98), 17OHP (females, r = 0.58; males, r = 0.84) and testosterone (females, r = 0.83; males, r = 0.97) were observed. Concordance between 3 alpha-AG and delta 4A was observed in 90% of all samples, and in 91% between 3 alpha-AG and testosterone. Our study demonstrates that 3 alpha-AG is a valid marker of control and its determination appears to be a reliable tool to monitor CAH.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008297 Male Males
D012016 Reference Values The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality. Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000312 Adrenal Hyperplasia, Congenital A group of inherited disorders of the ADRENAL GLANDS, caused by enzyme defects in the synthesis of cortisol (HYDROCORTISONE) and/or ALDOSTERONE leading to accumulation of precursors for ANDROGENS. Depending on the hormone imbalance, congenital adrenal hyperplasia can be classified as salt-wasting, hypertensive, virilizing, or feminizing. Defects in STEROID 21-HYDROXYLASE; STEROID 11-BETA-HYDROXYLASE; STEROID 17-ALPHA-HYDROXYLASE; 3-beta-hydroxysteroid dehydrogenase (3-HYDROXYSTEROID DEHYDROGENASES); TESTOSTERONE 5-ALPHA-REDUCTASE; or steroidogenic acute regulatory protein; among others, underlie these disorders. Congenital Adrenal Hyperplasia,Hyperplasia, Congenital Adrenal,Adrenal Hyperplasias, Congenital,Congenital Adrenal Hyperplasias,Hyperplasias, Congenital Adrenal
D000375 Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time. Senescence,Aging, Biological,Biological Aging

Related Publications

L A Lopes, and C Catzeflis, and I Cicotti, and C Rey, and P C Sizonenko
November 1994, European journal of endocrinology,
L A Lopes, and C Catzeflis, and I Cicotti, and C Rey, and P C Sizonenko
June 2000, Endocrine reviews,
L A Lopes, and C Catzeflis, and I Cicotti, and C Rey, and P C Sizonenko
January 2005, Journal for specialists in pediatric nursing : JSPN,
L A Lopes, and C Catzeflis, and I Cicotti, and C Rey, and P C Sizonenko
September 2020, The New England journal of medicine,
L A Lopes, and C Catzeflis, and I Cicotti, and C Rey, and P C Sizonenko
December 1990, The New England journal of medicine,
L A Lopes, and C Catzeflis, and I Cicotti, and C Rey, and P C Sizonenko
February 2004, Nihon rinsho. Japanese journal of clinical medicine,
L A Lopes, and C Catzeflis, and I Cicotti, and C Rey, and P C Sizonenko
March 1996, Lijecnicki vjesnik,
L A Lopes, and C Catzeflis, and I Cicotti, and C Rey, and P C Sizonenko
October 1998, Clinical endocrinology,
L A Lopes, and C Catzeflis, and I Cicotti, and C Rey, and P C Sizonenko
February 2006, Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego,
L A Lopes, and C Catzeflis, and I Cicotti, and C Rey, and P C Sizonenko
July 2009, European journal of pediatrics,
Copied contents to your clipboard!